0N5A Stock Chart & Stats
€1.54
€0.07(4.58%)
At close: 4:00 PM EST
€1.54
€0.07(4.58%)
Day’s Range― - ―
52-Week Range€1.35 - €2.58
Previous CloseN/A
Volume9.00
Average Volume (3M)4.00
Market Cap
€26.20M
Enterprise Value€28.81
Total Cash (Recent Filing)€286.00K
Total Debt (Recent Filing)€3.97M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding14,716,976
10 Day Avg. Volume7
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.27
Price to Sales (P/S)1.58
P/FCF Ratio-9.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsAn approximately 82% TTM gross margin indicates attractive product-level economics in the implant business. If maintained, this provides meaningful contribution from each sale and gives management a foundation to improve operating leverage, although the benefit currently does not offset the company’s broader cost base.
Manageable LeverageLow leverage and positive equity provide a balance-sheet cushion while the company works to improve profitability. A less debt-heavy capital structure can reduce financing pressure, preserve strategic flexibility, and make it easier to direct available resources toward product development and commercial execution.
Focused Orthopedic Product PlatformA focused portfolio of orthopedic and trauma implants, supported by related instruments, gives the company a defined position in essential surgical procedures. The product platform can support repeat commercial relationships with hospitals, distributors, and surgeons as product adoption and procedure volumes develop.
Bears Say
Persistent Net LossesPersistent losses show that strong gross profitability has not yet translated into a sustainable earnings model. Continued operating deficits can erode equity over time, limit internally funded investment, and make the company more dependent on external financing or other measures to support its strategy.
Ongoing Cash BurnConsistently negative operating and free cash flow indicates that the core business is not currently self-funding. Ongoing cash consumption reduces financial flexibility, increases the importance of working-capital and cost control, and may require additional funding before growth investments can be sustained internally.
Weakening Revenue MomentumThe TTM revenue decline signals weakening commercial momentum after a period of relatively stable sales. Lower revenue makes it harder to absorb fixed operating costs, limits the ability to realize scale benefits from high gross margins, and raises the risk that profitability recovery will take longer.
0N5A FAQ
What was aap Implantate AG’s price range in the past 12 months?
aap Implantate AG lowest share price was €1.35 and its highest was €2.58 in the past 12 months.
What is aap Implantate AG’s market cap?
aap Implantate AG’s market cap is €26.20M.
When is aap Implantate AG’s upcoming earnings report date?
aap Implantate AG’s upcoming earnings report date is Aug 18, 2027 which is in 344 days.
How were aap Implantate AG’s earnings last quarter?
aap Implantate AG released its earnings results on Aug 17, 2026. The company reported -€0.078 earnings per share for the quarter.
Is aap Implantate AG overvalued?
According to Wall Street analysts aap Implantate AG’s price is currently Overvalued.
Does aap Implantate AG pay dividends?
aap Implantate AG does not currently pay dividends.
What is aap Implantate AG’s EPS estimate?
aap Implantate AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does aap Implantate AG have?
aap Implantate AG has 14,716,976 shares outstanding.
What happened to aap Implantate AG’s price movement after its last earnings report?
aap Implantate AG reported an EPS of -€0.078 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of aap Implantate AG?
Currently, no hedge funds are holding shares in GB:0N5A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aap Implantate Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
aap Implantate AG
Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international regions. Its primary offerings feature LOQTEQ, an advanced anatomical plating system crucial for fracture treatment, in addition to a diverse selection of cannulated screws, conventional plates, and standard screws. Products are distributed under the 'aap' brand, reaching customers directly, including hospitals, purchasing syndicates, and hospital groups, as well as indirectly via its network of distributors. aap Implantate AG was founded in 1990 and maintains its corporate headquarters in Berlin, Germany.
Technical Analysis
Carl Zeiss Meditec
―
Eckert & Ziegler Strahlen und Medizintechnik
―
Geratherm Medical
―
MagForce AG
―
elexxion AG
―